Joras Oncology Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 27-05-2024
- Paid Up Capital ₹ 0.10 M
as on 27-05-2024
- Company Age 13 Year, 3 Months
- Last Filing with ROC 31 Mar 2017
- Open Charges ₹ 1.30 M
as on 27-05-2024
About Joras Oncology
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.30 M.
Sunil Kamble, Ashwin Prakash, Ashish Khorgade, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24233PN2011PTC155916
- Company No.
155916
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Sep 2011
- Date of AGM
30 Sep 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Joras Oncology Private Limited offer?
Joras Oncology Private Limited offers a wide range of products and services, including Allopathic Cough Syrup, Dextromethorphan Cough Syrup, Mineral Supplement, Iron Syrup, Anti Cancer Injection, Paclitaxel Injections.
Who are the key members and board of directors at Joras Oncology?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilesh Belhe  | Director | 02-Sep-2011 | Current |
| Sunil Kamble | Director | 09-Mar-2017 | Current |
| Ashwin Prakash | Director | Current | |
| Ashish Khorgade | Director | 02-Sep-2011 | Current |
| Sagar Dhumal | Director | 02-Sep-2011 | Current |
Financial Performance and Corporate Structure Insights of Joras Oncology.
Joras Oncology Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Joras Oncology?
In 2017, Joras Oncology had a promoter holding of 99.98% and a public holding of 0.02%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Pune Peoples Co-Op Bank Ltd Creation Date: 12 Aug 2015 | ₹1.30 M | Open |
How Many Employees Work at Joras Oncology?
Unlock and access historical data on people associated with Joras Oncology, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Joras Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Joras Oncology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
